Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.64
ARNA's Cash to Debt is ranked higher than
62% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ARNA: 2.64 )
ARNA' s 10-Year Cash to Debt Range
Min: 0.46   Max: 11204.39
Current: 2.64

0.46
11204.39
Equity to Asset 0.26
ARNA's Equity to Asset is ranked higher than
54% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARNA: 0.26 )
ARNA' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.98
Current: 0.26

0.07
0.98
F-Score: 3
Z-Score: -3.13
M-Score: -4.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -283.08
ARNA's Operating margin (%) is ranked higher than
64% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. ARNA: -283.08 )
ARNA' s 10-Year Operating margin (%) Range
Min: -2405.23   Max: -28.18
Current: -283.08

-2405.23
-28.18
Net-margin (%) -151.35
ARNA's Net-margin (%) is ranked higher than
68% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. ARNA: -151.35 )
ARNA' s 10-Year Net-margin (%) Range
Min: -2421.99   Max: -23.88
Current: -151.35

-2421.99
-23.88
ROE (%) -50.98
ARNA's ROE (%) is ranked higher than
68% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. ARNA: -50.98 )
ARNA' s 10-Year ROE (%) Range
Min: -7209.86   Max: -3.29
Current: -50.98

-7209.86
-3.29
ROA (%) -15.89
ARNA's ROA (%) is ranked higher than
78% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ARNA: -15.89 )
ARNA' s 10-Year ROA (%) Range
Min: -201.16   Max: -3.2
Current: -15.89

-201.16
-3.2
ROC (Joel Greenblatt) (%) -126.64
ARNA's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. ARNA: -126.64 )
ARNA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -759.39   Max: -30.02
Current: -126.64

-759.39
-30.02
Revenue Growth (%) 35.10
ARNA's Revenue Growth (%) is ranked higher than
94% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. ARNA: 35.10 )
ARNA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 35.1
Current: 35.1

0
35.1
EBITDA Growth (%) -70.30
ARNA's EBITDA Growth (%) is ranked higher than
51% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. ARNA: -70.30 )
ARNA' s 10-Year EBITDA Growth (%) Range
Min: -70.3   Max: 74.6
Current: -70.3

-70.3
74.6
EPS Growth (%) -57.10
ARNA's EPS Growth (%) is ranked higher than
53% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ARNA: -57.10 )
ARNA' s 10-Year EPS Growth (%) Range
Min: -57.1   Max: 104.7
Current: -57.1

-57.1
104.7
» ARNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ARNA Guru Trades in Q4 2013

Paul Tudor Jones 45,133 sh (New)
Ken Fisher 11,000 sh (New)
Steven Cohen 500,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
Q1 2014

ARNA Guru Trades in Q1 2014

Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

ARNA Guru Trades in Q2 2014

Jim Simons 57,355 sh (New)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
Q3 2014

ARNA Guru Trades in Q3 2014

Jim Simons 773,155 sh (+1248.02%)
Ken Fisher 11,000 sh (unchged)
Murray Stahl 45,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2013-12-31 New Buy$4.08 - $6.66 $ 4.12-21%11000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.10
ARNA's P/B is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. ARNA: 12.10 )
ARNA' s 10-Year P/B Range
Min: 0.63   Max: 29.43
Current: 12.1

0.63
29.43
P/S 26.60
ARNA's P/S is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. ARNA: 26.60 )
ARNA' s 10-Year P/S Range
Min: 7.58   Max: 106
Current: 26.6

7.58
106
EV-to-EBIT -8.11
ARNA's EV-to-EBIT is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARNA: -8.11 )
ARNA' s 10-Year EV-to-EBIT Range
Min: -90.1   Max: 0.4
Current: -8.11

-90.1
0.4
Current Ratio 3.73
ARNA's Current Ratio is ranked higher than
68% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARNA: 3.73 )
ARNA' s 10-Year Current Ratio Range
Min: 1.68   Max: 91.72
Current: 3.73

1.68
91.72
Quick Ratio 3.52
ARNA's Quick Ratio is ranked higher than
68% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. ARNA: 3.52 )
ARNA' s 10-Year Quick Ratio Range
Min: 1.68   Max: 91.72
Current: 3.52

1.68
91.72

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.29
ARNA's Price/Tangible Book is ranked higher than
68% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. ARNA: 13.29 )
ARNA' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 25.66
Current: 13.29

0.62
25.66
Price/Median PS Value 1.22
ARNA's Price/Median PS Value is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ARNA: 1.22 )
ARNA' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.97
Current: 1.22

0.39
2.97
Earnings Yield (Greenblatt) -12.00
ARNA's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. ARNA: -12.00 )
ARNA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 247.5   Max: 30966.3
Current: -12

247.5
30966.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RN3.Germany
Arena Pharmaceuticals, Inc., was incorporated in the state of Delaware in April 14, 1997, and commenced operations in July 1997. The Company is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ, its internally discovered drug for chronic weight management in adults who are overweight with a comorbidity or obese, is its first and only drug approved for marketing by any regulatory agency. In June 2012, the U.S. Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company is engaged in commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. Its programs include: BELVIQ, for chronic weight management; APD811, an orally available agonist of the prostacyclin (IP) receptor, is an internally discovered investigational drug candidate intended for the treatment of Pulmonary Arterial Hypertension; Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases; APD334, an orally available agonist of the S1P1 receptor, is an internally discovered investigational drug candidate intended for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis; APD371, an orally available agonist of the cannabinoid 2 receptor, is an internally discovered investigational drug candidate intended for the treatment of pain; GPR119, represents pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. The Company's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, granted Eisai Inc., and Eisai Inc.'s parent company, Eisai Co. Ltd. exclusive rights to commercialize BELVIQ in the United States. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company's research and development programs involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. In the United States, the Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, US Environmental Protection Agency, California Environmental Protection Agency, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the CSA and other federal, state or local regulations.
» More Articles for ARNA

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
comment on ARNA Mar 15 2013 
comment on ARNA Mar 02 2013 
WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark... Nov 25 2014
Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark... Nov 25 2014
24 NOVDelta Lloyd Bank priced Arena 2014-II securitisation Nov 24 2014
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference Nov 24 2014
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference Nov 24 2014
ARENA PHARMACEUTICALS INC Financials Nov 14 2014
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference Nov 13 2014
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference Nov 13 2014
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? Nov 13 2014
10-Q for Arena Pharmaceuticals, Inc. Nov 08 2014
ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study... Nov 06 2014
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study... Nov 06 2014
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference Nov 05 2014
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference Nov 05 2014
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows Nov 04 2014
Arena Pharma's 'Belviq' potential Nov 03 2014
Arena Pharmaceuticals Reports Q3 Loss, Shares Surge 6% Nov 03 2014
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results Nov 03 2014
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK